Respiratory events associated with concomitant opioid and sedative use among Medicare beneficiaries with chronic obstructive pulmonary disease

Tham Thi Le, Siyeon Park, Michelle Choi, Marniker Wijesinha, Bilal Khokhar, Linda Simoni-Wastil

ABSTRACT

Background Opioids and sedatives are commonly prescribed in chronic obstructive pulmonary disease (COPD) patients for symptoms of dyspnoea, pain, insomnia, depression and anxiety. Older adults are advised to avoid these medications due to increased adverse events, including respiratory events. This study examines respiratory event risks associated with concomitant opioid and sedative use compared with opioid use alone in older adults with COPD.

Methods A 5% nationally representative sample of Medicare beneficiaries with COPD and opioid use between 2009 and 2013 was used for this retrospective cohort study. Current and past concomitant use were identified using drug dispensed within 7 days from the censored date: at respiratory event, at death, or at 12 months post index. Concomitant opioid and sedative use were categorised into no overlap (opioid only), 1 to 10, 11 to 30, 31 to 60 and >60 days of total overlap. The primary outcome was hospitalisation or emergency department (ED) visits for respiratory events (COPD exacerbations or respiratory depression). Propensity score matching was implemented and semi-competing risk models were used to address competing risk by death.

Results Among 48,120 eligible beneficiaries, 1810 (16.7%) concomitant users were matched with 9050 (83.3%) opioid only users. Current concomitant use of 1 to 10, 11 to 30 and 31 to 60 days was associated with increased respiratory events (HRs (95% CI): 2.8 (1.2 to 7.3), 9.3 (4.9 to 18.2) and 5.7 (2.5 to 12.5), respectively), compared with opioid only use. Current concomitant use of >60 days or past concomitant use of ≤60 days was not significantly associated with respiratory events. Consistent findings were found in sensitivity analyses, including in subgroup analysis of non-benzodiazepine sedatives. Additionally, current concomitant use significantly increased risk of death.

Conclusion Short-term and medium-term current concomitant opioid and sedative use significantly increased risk of respiratory events and death in older COPD Medicare beneficiaries. Long-term past concomitant users, however, demonstrated lower risks of these outcomes, possibly reflecting a healthy user effect or developed tolerance to the effects of these agents.

Key messages

- This nationally representative study of older Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) examines respiratory event risks associated with current and past concomitant opioid and sedative use compared to opioid use only. Propensity score matching and semi-competing risk models were used to account for potential confounding by indication and competing risk by death.
- There was variation in adverse effects of concomitant opioid and sedative use. Short-term (1 to 10 days) or medium-term (11 to 60 days) current concomitant opioid and sedative use, including both benzodiazepines and non-benzodiazepine sedatives, significantly increased risks of respiratory events; while any medium-term concomitant use increased death, compared with opioid only use. Long-term past concomitant use appears to be associated with reduced risks of these outcomes.
- Concomitant opioid and sedative use should be avoided or closely monitored in older adults with COPD.

INTRODUCTION

The common use of opioids in the Medicare population remains a concern due to adverse risks, including respiratory depression, overdose and death. Risk of these adverse events increases when opioids are used concurrently with other agents with similar effects on the respiratory system. In particular, concomitant use of opioids with benzodiazepines and non-benzodiazepine sedatives can lead to an increased risk of respiratory depression. Concomitant use significantly increases risk of overdose or death compared with use of either medication alone. Both opioids and benzodiazepines are recommended to be avoided in older adults according to the American Geriatric Society’s Beers Criteria.
Patients with chronic obstructive pulmonary disease (COPD) are more likely to receive opioid prescriptions compared with those without COPD. Opioids are used for a multitude of comorbid conditions and symptoms in COPD patients, including pain, refractory dyspnoea and cough. Between one-fourth to two-thirds of COPD patients have received a prescription for opioids, and close to 18% of COPD patients use benzodiazepine or non-benzodiazepine sedatives. In the general population, around 1 in 10 opioid users are co-prescribed benzodiazepines or sedatives. Among Medicare beneficiaries, about one-fourth have concomitant opioid and sedative prescriptions.

Widespread use of opioids and sedatives in COPD patients is attributable to their higher prevalence of pain, dyspnoea and mental disorders. However, such use is controversial because there is little evidence of benefit or safety associated with opioids and sedatives for dyspnoea. Some studies indicate low doses of opioids or sedatives are beneficial for breathlessness and associate use with no increased respiratory event risks in COPD patients. Other research has found increased respiratory depression or exacerbations in COPD patients with opioid use. Several studies have found benzodiazepines and other sedatives may increase respiratory adverse events in COPD patients. These mixed findings may be due to a number of factors, including differences in the populations studied, outcome definitions and/or severity of COPD. As well, there is potential confounding by indication when opioids or sedatives are used for dyspnoea, which is a predictor of COPD exacerbation and death. Studies to date have failed to account for recency of opioid and/or sedative use relative to the respiratory events. Finally, the competing risk of death plays a key role. Employing methods to alleviate confounding by indication and competing risks are crucial to generate valid findings in examining risks of opioids and sedatives in COPD patients.

Respiratory event risks associated with concomitant opioid and sedative use are under-investigated in COPD patients, particularly in older adults who commonly use these medications. In particular, the depressive effects of opioids and sedatives on the respiratory system might be a concern in patients with COPD whose respiratory function is already compromised. Ekström et al found increased risk of death (but did not find increased risk of COPD hospitalisations) in a very severe COPD cohort aged 45 years or older with concomitant opioid and benzodiazepine use. In a recent case control study of older Medicare beneficiaries with COPD, increased hospitalisations for respiratory conditions (ie, asthma, COPD, respiratory inflammation, bronchitis) were associated with concomitant opioid and benzodiazepine users.

Our study used a nationally representative Medicare sample to examine the risk of respiratory events in COPD beneficiaries with concomitant opioid and sedative use compared with those with opioid use alone. We applied a semi-competing risk framework and accounted for the recency of drug exposure to estimate risks associated with concomitant opioid and sedative use.

METHODS

Study design and cohort criteria

This retrospective cohort study used a 5% nationally representative sample of Medicare beneficiary claims data between 1 January 2009 and 31 December 2013. The study cohort included beneficiaries with a diagnosis of COPD and at least one opioid prescription post COPD diagnosis. COPD diagnosis was a flagged variable defined in the Medicare claims by the Center for Medicare and Medicaid Services (the provider of the data), which used Medicare claims since 1999. The algorithm to define COPD (International Classification of Disease, Ninth Revision (ICD-9) codes 490, 491.x, 492.x, 494.x, 496) applied any claim diagnosis and required: (1) at least one inpatient, skilled nursing facility or home health agency claim; or (2) at least two outpatient or carrier claims. The index date was the date of first opioid prescription between 1 January 2010 and 1 January 2013. We excluded beneficiaries under 65 years old. The study used a new user design, requiring beneficiaries to have at least 12 months without opioid or sedative prescriptions prior to the index date. To adequately capture the covariates, exposures and outcomes, beneficiaries were required to have continuous enrolment in Medicare Parts A, B and D for 12 months pre-index and 12 months post-index date, or continuous enrolment until they died within 12 months after the index date. Individuals with Medicare Advantage (Part C) plans were excluded because their claims were not available in the data. In addition, beneficiaries were excluded if they had cancer diagnoses, were admitted to hospice or long-term care during the study period, switched between opioids and sedatives (used both opioids and sedatives but not concomitantly) and received injectable prescription opioids, as conversion factors for injection opioids are different from oral opioids.

Study participants were censored at 12 months post index (those without respiratory events or death), at the time of respiratory event or at death (those without respiratory events). In beneficiaries with respiratory and death within 12 months, time to death is recorded for use in the semi-competing risks model.

Exposure

A list of the medications included in our study is provided in Supplementary 1 (see online supplementary file 1). Opioid and sedative use was identified on each day during follow-up using Medicare Part D data. Concomitant use was defined as overlapping days of use of both opioids and sedatives. We categorised the main exposure variable into five categories: (1) opioid only, (2) concomitant with 1 to 10 days overlap, (3) concomitant with 11 to 30 days overlap, (4) concomitant with 31 to 60 days overlap, and (5) opioid and sedative use alone.
overlap and (5) concomitant with >60 days overlap. We additionally used these five categories to define past or current use. Current users were those with concomitant or opioid only use within 7 days of the censored date. Past users had discontinued concomitant or opioid only use at least 7 days prior to the censored date.

We also measured total opioid days supplied and cumulative morphine equivalent dose (MED) to account for the level of exposure to opioids. MED was equal to the quantity unit for each prescription multiplied by dosage strength and morphine milligram equivalency conversion factor.52

Outcomes
Primary study outcomes were hospitalisation and emergency department (ED) visits for respiratory events, including respiratory depression and COPD exacerbations. Respiratory events were captured by the ICD-9 codes 518.81 to 518.84, 518.51 to 518.53, 518.4, 518.5, 799.1, 490, 491, 492, 493, 494 and 496. We recorded death as a competing risk that could preclude the primary outcome.49

Covariates
Baselines covariates were defined during the 12 months prior to index date. Covariates measured in the study were demographic factors (age, gender, race), baseline respiratory events, baseline supplemental oxygen use (as a proxy for COPD severity),35 comorbidities known to predict respiratory events as assessed in literature (pain-related conditions, cardiovascular diseases, mental illnesses, musculoskeletal diseases, osteoporosis, chronic kidney disease, peripheral vascular disease and dementia)21 25 38 and COPD medications (antibiotics, bronchodilators and oral corticosteroids).

Patient and public involvement
Patients were not involved in the planning, design, data collection or the conduct of this study. The study results will be disseminated through scientific journals.

Statistical analyses
X² tests and t-tests were used for categorical and continuous variables, respectively, to compare characteristics of concomitant versus opioid only users.

To alleviate potential confounding by indication when comparing concomitant users with opioid only users, we implemented propensity score matching for the primary analysis.52 Logistic regression was used to estimate propensity scores of concomitant use. Potential confounders and opioid total days supplied and cumulative MED were the independent variables in the model (the list of independent variables are provided in the Supplementary 2) (see online supplementary file 2). Due to the imbalance of study participants in the two exposure groups, we operationalised a 1:5 ratio to match concomitant with opioid only users, which was performed without replacement using a caliper size of 0.001. Before matching, the individuals in the end tails (5th and 95th percentiles) of the propensity score distribution were excluded to reduce unmeasured confounding.54 Covariates were examined between the two exposure groups after matching to check for matching performance.

A semi-competing risks Cox proportional hazards model, implemented via the SemiCompRisks package in R V.3.5.2, was used to estimate relative risks of respiratory events and death. In the semi-competing risk framework there are terminal events (death) and non-terminal events (respiratory). The framework aims to address the semi-competing risk of respiratory events by death (ie, death prevents respiratory events from occurring but not vice versa). Specifically, the semi-competing risks framework addresses a potential dependence between respiratory events and death by adding a patient-specific frailty to the standard proportional hazard regression model. A more detailed description of the semi-competing risks framework is available from Haneuse and colleagues,59 56 and an example of its application is described elsewhere.57

To compare with the results of semi-competing risk models, we also implemented standard Cox proportional hazards (censoring death) and Fine-Gray competing-risk models.49

We also conducted several sensitivity analyses that: (1) defined current use as use within 30 days of the censored date, (2) included subgroup analyses among more severe COPD beneficiaries who had baseline oxygen supplementation, (3) estimated multivariable models using all eligible beneficiaries without propensity score matching and (4) conducted subgroup analysis of only non-benzodiazepine sedative concomitant use, with users of benzodiazepines to be excluded.

Analyses were implemented using SAS V.9.4 and R V.3.5.2. HR and 95% CIs were reported.

RESULTS
A total of 48 120 beneficiaries with COPD and opioid use met the study criteria, 84% of whom were white and 86% were female, with mean age of 77 years (SD of 7). Among these, 2296 (4.8%) beneficiaries had concomitant opioid and sedative use, while the remaining 45 824 (94.2%) beneficiaries used only opioids.

Concomitant users were more likely to be younger and female than opioid only users (table 1). Beneficiaries with opioid only use had higher baseline respiratory event rates, cardiovascular diseases, chronic kidney disease, pain conditions, musculoskeletal diseases, osteoporosis and dementia than concomitant users. In addition, the opioid only group used more baseline anticholinergics, beta-agonists and inhaled corticosteroids than concomitant users. Both groups had similar use of oxygen supplementation, antibiotics, theophylline and oral corticosteroids. Concomitant users had higher cumulative MED and total opioid days supplied than opioid only users (table 1).

After propensity score matching, 1810 concomitant users were matched with 9050 opioid only users...
### Table 1  Characteristics of study cohort before and after matching

| Covariates                      | Before matching | After matching | P value | P value |
|---------------------------------|-----------------|----------------|---------|---------|
|                                 | Concomitant     | Opioid only    | n=2296  | n=45 824| Before matching | Opioid only    | n=1810  | n=9050  |         |
|                                 | Age (years)     |                |         |         |                       |               |          |         |         |
| 65–74                           | 1200 (52.3)     | 18 691 (40.8)  | <0.01   | 0.79    |
| 75–84                           | 836 (36.4)      | 19 377 (42.3)  | <0.01   | 0.69    |
| ≥85                             | 260 (11.3)      | 7 756 (16.9)   | <0.01   | 0.68    |
| Females                         | 1579 (68.8)     | 29 412 (64.2)  | <0.01   |         |
|                                 | Race            |                | <0.01   |         |
| White                           | 1936 (84.3)     | 37 759 (82.4)  | <0.01   | 0.88    |
| Black                           | 155 (6.8)       | 4 350 (9.5)    | <0.01   | 0.59    |
| Hispanic                        | 96 (4.2)        | 1 715 (3.7)    | <0.01   | 0.10    |
| Asian                           | 109 (4.7)       | 2 000 (4.4)    | <0.01   | 0.63    |
|                                 | Comorbidities   |                | <0.01   |         |
| Respiratory events*             | 568 (24.7)      | 17 511 (38.2)  | <0.01   | 0.88    |
| Diabetes                        | 329 (14.3)      | 10 514 (22.9)  | <0.01   | 0.59    |
| Heart failure                   | 196 (8.5)       | 6 049 (13.2)   | <0.01   | 0.10    |
| Ischaemic heart disease         | 367 (16.0)      | 11 327 (24.7)  | <0.01   | 0.94    |
| Acute myocardial infarction     | 19 (0.8)        | 564 (1.2)      | 0.08    | 0.78    |
| Stroke                          | 73 (3.2)        | 2 414 (5.3)    | <0.01   | 0.73    |
| Hypertension                    | 752 (32.8)      | 23 846 (52.0)  | <0.01   | 0.73    |
| Hyperlipidaemia                 | 632 (27.5)      | 20 712 (45.2)  | <0.01   | 0.79    |
| Peripheral vascular disease     | 202 (8.8)       | 6 075 (13.3)   | <0.01   | 0.68    |
| Chronic kidney disease          | 204 (8.9)       | 5 247 (11.5)   | <0.01   | 0.69    |
| Pain†                           | 382 (16.6)      | 10 123 (22.1)  | <0.01   | 0.50    |
| Musculoskeletal disease‡        | 422 (18.4)      | 12 439 (27.1)  | <0.01   | 0.99    |
| Osteoporosis                    | 148 (6.4)       | 4 902 (10.7)   | <0.01   | 0.93    |
| Mental disorders§               | 299 (13.0)      | 5 198 (11.3)   | 0.01    | 0.89    |
| Dementia                        | 64 (2.8)        | 1 943 (4.2)    | <0.01   | 0.58    |
|                                 | Medication use  |                | <0.01   |         |
| Antibiotics                     | 368 (16.0)      | 7 270 (15.9)   | 0.84    | 0.83    |
| Anticholinergic                 | 218 (9.5)       | 7 016 (15.3)   | <0.01   | 0.53    |
| Beta-agonists                   | 544 (23.7)      | 14 214 (31.0)  | <0.01   | 0.81    |
| Inhaled corticoids              | 544 (23.7)      | 13 207 (28.8)  | <0.01   | 0.56    |
| Combined corticoids             | 267 (11.6)      | 7 419 (16.2)   | <0.01   | 0.78    |
| Oral corticoids                 | 557 (24.3)      | 11 733 (25.6)  | <0.01   | 0.93    |
| Theophylline                    | 34 (1.5)        | 653 (1.4)      | 0.19    | 0.30    |
| Oxygen supplement               | 355 (15.5)      | 5 947 (13.0)   | 0.15    | 0.84    |
| Cumulative opioid MED (mg)¶     | <0.01           | <0.01          | <0.01   |         |
| <150                             | 44 (1.9)        | 9 160 (20.0)   | <0.01   | 0.85    |
| 150–350                          | 211 (9.2)       | 13 772 (30.1)  | <0.01   | 0.85    |
| 350–900                          | 494 (21.5)      | 10 788 (23.5)  | <0.01   | 0.85    |
| 900–2250                         | 592 (25.8)      | 6 795 (14.8)   | <0.01   | 0.85    |
| >2250                            | 955 (41.6)      | 5 309 (11.6)   | <0.01   | 0.85    |
| Opioid total days supplied      | <0.01           | <0.01          | <0.01   | 0.97    |
| 1–10                            | 192 (8.4)       | 20 594 (44.9)  | <0.01   | 0.97    |

Continued
Table 1  Continued

| Covariates | Before matching | Opioid only n=45,824 | P value | After matching | Concomitant n=1,810 | Opioid only n=9,050 | P value |
|------------|----------------|---------------------|---------|----------------|---------------------|---------------------|---------|
| 11–30 | 439 (19.1) | 11,429 (24.9) | 439 (24.3) | 2197 (24.3) |
| 30–60 | 387 (16.9) | 5,494 (12.0) | 379 (20.9) | 1,893 (20.9) |
| 62–90 | 283 (12.3) | 2,263 (4.9) | 221 (12.2) | 1,041 (11.5) |
| >90 | 995 (43.3) | 6,044 (13.2) | 580 (32.0) | 2,954 (32.6) |

*COPD exacerbation and respiratory distress. †Chronic pain, fibromyalgia and migraine. ‡Arthropathy, arthritis, lupus and rheumatoid arthritis. §Depression, anxiety, bipolar and schizophrenia. ¶Morphine equivalent dose.

COPD, chronic obstructive pulmonary disease; MED, morphine equivalent dose.

All baseline covariates, including opioid total days supplied and cumulative MED, were similar between the two matched groups (Table 1). Mean (median) cumulative MED and total opioid days supplied in the matched cohort were 3021 (1125) mg and 98 (50) days, respectively. Compared with non-matched beneficiaries (n=37,260), matched beneficiaries (n=10,860) were younger, more likely to be female, had fewer comorbidities, and higher cumulative MED and total opioid days supplied (see online supplementary file 2).

In the propensity score matched cohort, among concomitant users there were 319 (17.6%) beneficiaries who experienced respiratory events without death. Mean (median) time to respiratory events was 146 (127), 157 (170), 126 (81), 124 (92), 168 (175) days respectively for opioid only users and concomitant users of 1 to 10, 11 to 30, 31 to 60 and >60 days. In addition, 53 (2.9%) beneficiaries died after respiratory events and 59 (3.3%) died without having respiratory events. In opioid only users, 16.2% had respiratory events without death, 2.7% died after respiratory events and 3.3% died without having respiratory events (Table 2).

Primary analyses

Table 3 shows the HRs of respiratory events and deaths from three models: (1) Cox proportional hazards, (2) Fine-Gray competing-risk and 3) semi-competing risks. Across all models, risks of respiratory events and death increased with total days of current concomitant use, then decreased in beneficiaries with 60+ days of current concomitant use, compared with opioid only users.

In the semi-competing risks models, beneficiaries with 11 to 30 days of current concomitant use had highest risks of respiratory events (HR 9.3, 95% CI 4.9 to 18.2), and those with 31 to 60 days of current concomitant use were at the greatest risk of death before respiratory events (HR 10.2, 95% CI 3.4 to 26.3). The risk of death after respiratory events was increased (HR 2.8, 95% CI 1.1 to 6.5) in current concomitant users of 11 to 30 days compared with opioid only users, as was the risk of death without respiratory events (HR 8.3, 95% CI 2.9 to 20.1). Past concomitant short-term use (<11 days) and past concomitant medium-term use (11 to 60 days) demonstrated no significant effect on respiratory events but on death compared with past use of opioid only. In addition, long-term (>60 days) past concomitant users had lower risks of respiratory events (HR 0.6, 95% CI 0.3 to 0.9) and death (HR 0.2, 95% CI 0.04 to 0.9) than past opioid only users.

Cox regression and Fine-Gray competing-risk models also show increased risks of respiratory events among concomitant users of 11 to 60 days (Table 3).

Cumulative MED was consistently associated with respiratory events in a dose-response manner, with risks of respiratory events increasing when cumulative MED increased. The risk of death was highest among those with cumulative MED of 350 mg to 900 mg (Table 3).

Sensitivity analyses

When extending the time window to define the current use of drugs to 30 days from the censored date, results
were relatively similar compared with the main analysis. Current concomitant users with 11 to 30 days had the highest HR of respiratory events (HR 9.5, 95% CI 4.9 to 18.6), and 31 to 60 days of current concomitant users had highest risk of death (HR 9.6, 95% CI 3.3 to 25.3). Past concomitant users of 60+ days had significantly lower risks of respiratory events and death (see online supplementary file 3).

In the subgroup analysis among COPD beneficiaries with oxygen supplementation at baseline, current concomitant users with 1 to 10 days had highest risks with oxygen supplementation at baseline, current concomitant users with 11 to 30 days had the highest HR of respiratory events (HR 9.5, 95% CI 4.9 to 18.6), and 31 to 60 days of current concomitant users were relatively similar compared with the main analysis.

Table 2 Respiratory events and death within 12 months follow-up in the matched cohort (n=10 860)

| N (column %) | Concomitant users (n=1810) | Opioid only users (n=9050) | Total (n=10 860) |
|-------------|----------------|----------------|----------------|
| Respiratory events without death | 319 (17.6%) | 1466 (16.2%) | 1785 (16.8%) |
| Respiratory events with death | 53 (2.9%) | 244 (2.7%) | 297 (2.7%) |
| Death without respiratory events | 59 (3.3%) | 296 (3.3%) | 355 (3.3%) |

Respiratory events=COPD exacerbation or respiratory depression. COPD, chronic obstructive pulmonary disease.

In the subgroup analysis among COPD beneficiaries with oxygen supplementation at baseline, current concomitant users with 1 to 10 days had highest risks with oxygen supplementation at baseline, current concomitant users with 11 to 30 days had the highest HR of respiratory events (HR 9.5, 95% CI 4.9 to 18.6), and 31 to 60 days of current concomitant users were relatively similar compared with the main analysis.

Table 3 Associations of concomitant opioid and sedative use with respiratory events and death (HRs and 95% CI)

| Covariates | Respiratory events | Death | Competing-risk | Respiratory events | Death | Death before respiratory events | Death after Respiratory events |
|------------|-------------------|-------|----------------|-------------------|-------|-----------------------------|-----------------------------|
| Past concomitant users (days)* | | | | | | | |
| 1–10 | 1.050 (0.858–1.285) | 0.702 (0.465–1.060) | 1.165 (0.945–1.437) | 0.702 (0.465–1.059) | 1.024 (0.765–1.357) | 0.826 (0.459–1.388) | 0.444 (0.195–0.902) |
| 11–30 | 0.884 (0.707–1.1006) | 0.803 (0.533–1.210) | 0.879 (0.689–1.122) | 0.803 (0.534–1.208) | 0.827 (0.609–1.105) | 0.597 (0.300–1.079) | 0.944 (0.496–1.693) |
| 31–60 | 0.944 (0.695–1.283) | 1.261 (0.777–2.045) | 0.861 (0.608–1.222) | 1.261 (0.779–2.039) | 0.888 (0.577–1.369) | 0.972 (0.414–1.970) | 1.557 (0.666–3.221) |
| >60 | 0.724 (0.497–1.054) | 0.401 (0.149–1.075) | 0.786 (0.535–1.153) | 0.401 (0.150–1.068) | 0.557 (0.336–0.909) | 0.244 (0.035–0.858) | 0.527 (0.075–2.000) |
| Current concomitant users (days)* | | | | | | | |
| 1–10 | 1.511 (0.937–2.437) | 1.245 (0.516–3.005) | 1.641 (0.989–2.720) | 1.245 (0.509–3.043) | 2.801 (1.173–7.268) | 3.303 (0.826–11.168) | 0.233 (0.006–1.416) |
| 11–30 | 3.161 (2.291–4.360) | 3.266 (1.945–5.460) | 2.529 (1.735–3.688) | 3.266 (1.916–5.569) | 9.281 (4.905–18.249) | 8.314 (2.945–20.134) | 2.806 (1.120–6.558) |
| 31–60 | 2.223 (1.458–3.391) | 3.560 (1.953–6.489) | 1.810 (1.116–2.934) | 3.560 (1.983–6.695) | 5.714 (2.462–12.482) | 10.185 (3.459–26.342) | 2.529 (0.699–7.762) |
| >60 | 1.274 (0.934–1.739) | 1.400 (0.782–2.506) | 1.164 (0.826–1.641) | 1.400 (0.788–2.487) | 1.212 (0.762–1.917) | 0.770 (0.216–1.986) | 1.827 (4.003) |
| Cumulative MED (mg)* | | | | | | | |
| 150–350 | 1.543 (1.053–2.263) | 1.676 (0.868–3.236) | 1.506 (0.994–2.281) | 1.761 (0.867–3.241) | 1.925 (1.106–3.094) | 2.379 (0.947–7.234) | 1.077 (0.419–3.198) |
| 350–900 | 1.716 (1.188–2.478) | 1.712 (0.906–3.232) | 1.721 (1.155–2.564) | 1.712 (0.907–3.231) | 2.177 (1.250–3.456) | 2.680 (1.116–9.228) | 0.853 (0.348–2.242) |
| 900–2250 | 1.750 (1.212–2.526) | 1.516 (0.803–2.865) | 1.791 (1.202–2.668) | 1.516 (0.803–2.863) | 2.245 (1.297–3.559) | 2.286 (0.951–5.944) | 0.756 (0.372–1.679) |
| >2250 | 1.970 (1.364–2.845) | 1.291 (0.680–2.451) | 2.128 (1.428–3.172) | 1.291 (0.680–2.450) | 2.464 (1.416–3.895) | 1.944 (0.794–6.717) | 0.583 (0.238–1.655) |

*Reference group is cumulative use <150 mg.
†Reference group is cumulative use <150 mg.
MED, morphine equivalent dose.
Past concomitant use was not associated with respiratory events or death. Cumulative MED was significantly associated with respiratory events and death with a dose-response effect in the third sensitivity analysis 3 and 4, but not in sensitivity analyses 1 and 2 (see online supplementary file 3).

**DISCUSSION**

In this national study of Medicare beneficiaries with COPD, current concomitant use of opioids and sedatives significantly increased risks of respiratory events, including COPD exacerbations and respiratory depression. In addition, current concomitant use was associated with an almost 10-fold increased risk of death compared with opioid use alone. There was a duration-response of the effects, with risks increasing from short (1 to 10 days) to medium (11 to 60 days) duration of concomitant use, while it was insignificant in longer (>60 days) current concomitant use.

The recency of concomitant opioid and sedative use (e.g., the time between the last concomitant exposure and the respiratory events) is crucial in evaluating risks. In this study, short and medium duration of past concomitant use was not associated with respiratory events or death, however, long-term (>60 days) past concomitant use decreased these risks. The reduced risks with long-term past and current concomitant use is likely the result of a healthy user effect. Healthy user effect relates to multiple characteristics of the patients that make them less likely to have adverse events, including disease severity, cognitive functions, frailty or adherence. New user design, propensity score matching and active comparator groups could alleviate healthy user effect biases. In addition, the reduced risk associated with long-term concomitant use may be attributable to the ability of certain patients to develop tolerance to opioids and sedatives as suggested in prior literature.

We also found increased risks of respiratory events when cumulative MED increased. This is indicative of potential opioid dosing effects in less severe and healthier COPD patients in the primary analysis. Sensitivity analyses demonstrated no associations when defining drug exposure recency as within 30 days, or when restricting to more severe COPD patients with oxygen supplementation.

Death is an important competing outcome to consider, as it would have precluded the occurrence of respiratory events in some patients. Appropriate approaches to account for the semi-competitive nature between respiratory events (non-terminal events) and deaths (terminal events) are necessary to achieve valid estimation of respiratory event risks. In this study, traditional Cox regression and Fine-Gray competing-risk models were found to underestimate the risks of the non-terminal events compared with the findings in semi-competing risk models. The use of a semi-competing risk framework facilitates a more proper approach for competing events between respiratory events and death, and is appropriate for broader use when compared with Cox proportional hazards and Fine-Gray competing-risk models.

Despite prior literature on risks of opioid and benzodiazepines in COPD patients, this is the first study to examine concomitant use of opioids with both benzodiazepines and non-benzodiazepine sedatives in older adults with COPD. Concomitant opioid and benzodiazepine use was associated with strong adverse effects including respiratory depressions, overdoses and death in prior literature. Both benzodiazepines and other sedatives have similar pharmacological effects on depressive respiratory symptoms. In the subgroup analysis of only concomitant use of opioids and non-benzodiazepine sedatives, we also found increased respiratory event risks. Thus, extending the investigation to concomitant use of opioids and all sedatives, not just benzodiazepines, makes this study highly relevant, especially when sedative use is common in older Medicare beneficiaries with COPD.

Ekström et al. investigated risks of concomitant opioids and benzodiazepines in a very severe COPD cohort with oxygen supplementation. The authors found low doses of concomitant use were associated with death but not with COPD hospitalisations. Additionally, we found similar but stronger effects than the findings in a study of older Medicare beneficiaries with COPD by Baillargeon et al. The following strengths of our study help explain differences in findings compared with these two studies. For one, both studies only included benzodiazepine sedatives. Second, our study used a new-user study design to avoid prevalent user bias, whereas Ekström and Baillargeon used prevalent users. Third, in addition to our new-user design, the use of propensity score matching reduced confounding by indication—a main challenge when examining concomitant use of opioids and sedatives in COPD patients. Fourth, the semi-competing risk framework used in this study properly accounts for the competing risk nature of respiratory events by death. Finally, we defined recency of drugs when examining adverse events which has been recommended as standard in pharmacoepidemiology studies. Inclusion of both current and past use in our study allows for more valid estimates of respiratory event risks based on the time of drug exposure.

Findings of our study have several implications. Our results lend support to the recommendation to avoid these drugs in older adults per the Beers criteria, particularly their concomitant use, even though concomitant use of opioids and sedatives in older Medicare beneficiaries with COPD is common. In addition, a significant proportion of beneficiaries had high cumulative MED use, which is more likely to increase risk of adverse events. Thus, more careful prescription management programmes for older adults with COPD may be needed. Physicians who prescribe opioids or sedatives to older COPD patients should carefully assess whether older beneficiaries are already prescribed these medications by others providers.

In addition, there is variation in effects of concomitant use, as illustrated by the wide intervals of estimates, the opposite effects in past and current concomitant use and the slight variation of findings across sensitivity analyses.
This variation in effects of concomitant use is likely due to the heterogeneous clinical profile in COPD patients.\(^6\) Thus, if opioids or sedatives are needed in older COPD patients, a personalised approach should be considered, along with close monitoring for possible adverse events. Finally, monitoring of opioid doses should be considered due to its impact on adverse events. Further research on effects of opioid and sedative dosing on COPD patients also is necessary.

Several limitations of this study require acknowledgement. First, this study uses administrative claims data; thus important predictors of COPD respiratory outcomes, such as smoking, lung function (forced expiratory volume in one second), frailty and body mass index could not be assessed, resulting in potential unmeasured confounding. Second, use of opioids and sedatives were assumed to be what was observed in the claims; however, patients may not have taken the medications as prescribed. To mitigate this problem, sensitivity analyses were implemented to define different time windows of current versus past drug exposure. Third, our study could not account for effects of sedative dose as no consistent conversion factors are available for all sedative agents. Fourth, there is potential bias if patients experienced hospitalisation for non-respiratory events during follow-up. Fifth, propensity score matching balanced opioid use and cumulative MED between concomitant and opioid only groups; however, this approach does not guarantee complete avoidance of immortal time bias in those who used opioids only and died before becoming concomitant users. Additional adjustment of opioid cumulative MED after matching was implemented to further reduce this residual bias. Finally, this study only included older Medicare beneficiaries who would be at higher risks of adverse events by opioids and sedatives than younger individuals. Future research should extend the study to other populations to examine the generalisability of these findings.

CONCLUSIONS
Current concomitant use of opioids and sedatives significantly increased respiratory event risks and death in older Medicare beneficiaries with COPD. However, long-term past concomitant users demonstrated lower risks. Understanding different factors associated with potential risks is critical to inform the use of opioids and sedatives in older adults with COPD.

**Contributors** TTL, SP, MC, LSN and BK contributed to the conception of the study. Statistical analyses were done by TTL, SP and MW. All co-authors contributed to the interpretation of data. TTL wrote the first draft of the manuscript and all authors critically revised the manuscript and approved the submitted version.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** The Institutional Review Board (IRB) of the University of Maryland, Baltimore, approved this study.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data may be obtained from a third party and are not publicly available. This study used the 5% Medicare claims called Chronic Conditions Data Warehouse provided by the Center for Medicare and Medicaid Services (CMS). The data is de-identified claims, the re-use of the data is only guaranteed under an approved Data Use Agreement by the CMS. CMS website: https://www2.cwdata.org/web/guest/home/CMS. Contact: HealthAPT, LLC. Attention: CCW Research Coordinator, 1401 50th Street, Suite 200, West Des Moines, IA 50266. Phone: 866-766-1915. Email: CCWHelp@gdit.com. Fax: 515-440-3159.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID ID** Tham Thi Le http://orcid.org/0000-0003-3648-5858

**REFERENCES**

1. Department of Health and Human Services Report. Opioid use in Medicare Part D remains concerning. Available: https://oig.hhs.gov/oei/reports/oei-02-18-00220.pdf
2. Karaca-Mandic P, Meara E, Morden NE. The growing problem of co-treatment with opioids and benzodiazepines. BMJ 2017;356:j2224.
3. Nadpara PA, Joyce AR, Murrell E, et al. Risk factors for serious prescription opioid-induced respiratory depression or overdose: comparison of commercially insured and Veterans health affairs populations. Pain Medicine 2018;19:79–96.
4. Lee LA, Caplan RA, Stephens LS, et al. Postoperative opioid-induced respiratory depression: a closed claims analysis. Anesthesiology 2015;122:659–65.
5. Dahan A, van der Schrier R, Smith T, et al. Averting opioid-induced respiratory depression without affecting analgesia. Anesthesiology 2018;128:1027–37.
6. Gupta K, Prasad A, Nagappa M, et al. Risk factors for opioid-induced respiratory depression and failure to rescue: a review. Curr Opin Anaesthesiol 2018;31:110–9.
7. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011;12:747–54.
8. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013;309:657–9.
9. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011;106:32–51.
10. Musich S, Wang SS, Slindie L, et al. Prevalence and characteristics associated with high dose opioid users among older adults. Geriatr Nurs 2019;40:31–4.
11. Jann M, Kennedy WK, Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdose deaths with opioid analgesics. J Pharm Pract 2014;27:5–16.
12. Overdyk FJ, Dwolling O, Mariano J, et al. Association of opioids and sedatives with increased risk of in-hospital cardiopulmonary arrest from an administrative database. PLoS One 2016;11:e0150214.
13. Izrailevyan I, Gui J, Overdyk FJ, et al. Risk factors for cardiopulmonary and respiratory arrest in medical and surgical hospital patients on opioid analgesics and sedatives. PLoS One 2018;13:e0194553.
14. Jay MA, Thomas BM, Nandi R, et al. Higher risk of opioid-induced respiratory depression in children with neurodevelopmental disability: a retrospective cohort study of 12 904 patients. Br J Anaesth 2017;118:239–46.
15. Davis MF, Behm B, Balachandran D. Looking both ways before crossing the street: assessing the benefits and risk of opioids in...
treating patients at risk of sleep-disordered breathing for pain and dyspnea. J Opioid Manag 2017;13:183–96.

16 Hernandez I, He M, Brooks MM, et al. Exposure-Response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries. JAMA Netw Open 2018;1:e180919.

17 Jones CM, McAninch JF. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med 2015;49:493–501.

18 Kandel DB, Hu M-C, Griesler P, et al. Increases from 2002 to 2015 in prescription and overdose deaths in combination with other substances. Drug Alcohol Depend 2017;178:501–11.

19 Bachhuber MA, Hennessy S, Cunningham CO, et al. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health 2016;106:686–92.

20 Laitinen L, Laribiä S, Nilsson O, et al. Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users. Eur J Clin Pharmacol 2016;72:869–76.

21 Gressler LE, Martin BC, Hudson TJ, et al. Relationship between concomitant benzodiazepine-opoid use and adverse outcomes among US veterans. Pain 2018;159:451–9.

22 By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227–46.

23 Roberts MH, Mapel DW, Hartry A, et al. Chronic pain and pain medication use in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc 2013;10:290–8.

24 Ekström M, Bornfalk-Hansson A, Abernethy A, et al. Low-dose opioids should be considered for symptom relief also in advanced chronic obstructive pulmonary disease (COPD). Evid Based Med 2015;20:1.

25 Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2016;48:683–93.

26 Ahmadi Z, Bernelid E, Currow DC, et al. Prescription of opioids for breathlessness in end-stage COPD: a national population-based study. Int J Chron Obstruct Pulmon Dis 2016;11:2651–7.

27 Make B, Dubey A, Hernandez LR, et al. Comorbidities of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis 2012;7:1.

28 Halvorsen T, Martinussen PE. Benzodiazepine use in COPD: empirical evidence from Norway. Int J Chron Obstruct Pulmon Dis 2015;10:1685.

29 Hwang CS, Kang EM, Kornegay CJ, et al. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002–2014. Am J Prev Med 2016;51:151–60.

30 Garg RK, Fouton-Kehoe D, Franklin GM. Patterns of opioid use and risk of opioid overdose death among Medicaid patients. Med Care 2017;55:661–8.

31 Dasgupta N, Funk MJ, Pratikas, et al. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med 2016;17:85–98.

32 Center for Medicare and Medicaid Services. Available: https://www2.cwwdata.org/web/guest/condition-categories

33 Hernandez I, He M, Brooks MM, et al. Exposure-Response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries. JAMA Netw Open 2018;1:e180919.

34 Barnes PJ, Celli BR. Systematic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165–82.

35 Garvey C, Criner GJ. Impact of comorbidities on the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;198:23–9.

36 Battaglia S, Bezzi M, Sferrazza Papa GF, Sferrazza GP. Are benzodiazepines and opioids really safe in patients with severe COPD? Minerva Med 2014;105:1–7.

37 Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev 2016;3:CD011008.

38 Ekström MP, Bornfalk-Hansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014;348:g445.

39 Ekström M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc 2015;12:1079–92.

40 Verberk CA, van den Beuken-van Everdingen MHJ, Schols JMGA, et al. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J 2017;50:1701153.

41 Jennings A-L, Davies AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:839–44.

42 Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 2009;64:910–5.

43 Currow DC, Ekström M, Johnson MJ. Overdosing on immediate-release morphine solution has predictable adverse effects. Eur Respir J 2017;50:170191.

44 Donovan LM, Malte CA, Specce LJ, et al. Risks of benzodiazepines in chronic obstructive pulmonary disease with comorbid posttraumatic stress disorder. Ann Am Thorac Soc 2019;16:82–90.

45 Chung W-S, Lai C-Y, Lin C-L, et al. Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study. Medicine 2015;94:e1110.

46 Vozoris NT, Stephenson AL. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2015;45:586–7.

47 Steer J, Norman EM, Afolabi OA, et al. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax 2016;71:117–21.

48 Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018;363:k3352.

49 Wise JP, Gray RJ. A proportional hazards model for the Subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.

50 Baillargeon J, Singh G, Guo Y-F, et al. Association of opioid and benzodiazepine use with adverse respiratory events in older adults with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2019;16:1245–51.

51 Center for Medicare and Medicaid Services. Chronic condition ICD-9. Available: https://www2.cwwdata.org/web/guest/condition-categories

52 Sanders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 2010;25:310–5.

53 Simoni-Wastila L, Wei Y-J, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother 2012;10:201–10.

54 Stürmer T, Rothman KJ, Avorn J, et al. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol 2010;172:843–54.

55 Alvesa D, Haneuse S, Lee C, et al. SemiCompRisks: an R package for independent and Cluster-Correlated analyses of Semi-Competing risks data. arXiv 2018.

56 Haneuse S, Lee KH. Semi-competing risks data analysis: accounting for death as a competing risk when the outcome of interest is nonterminal. Circ Cardiovasc Qual Outcomes 2016;9:322–31.

57 Jazić I, Schrag D, Sargent DJ, et al. Beyond composite endpoints analysis: semicompeting risks as an underutilized framework for cancer research. J Natl Cancer Inst 2016;108:djw154.

58 Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011;26:546–50.

59 Savage SR. Long-term opioid therapy: assessment of consequences and risks. J Pain Symptom Manage 1996;11:274–86.

60 Micheli S, Cassano GB, Frare F, et al. Long-Term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 1996;29:127–34.

61 Blacker DS. Pharmacodynamic considerations for moderate and deep sedation. Anesth Prog 2012;59:28–42.

62 Ekström M, Nilsson F, Abernethy A, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Eur Respir Soc 2015.

63 Roca J, Yargas C, Cano I, et al. Chronic obstructive pulmonary disease heterogeneity: challenges for health risk assessment, stratification and management. J Transl Med 2014;12:53.